BillionToOne Provides Guidance for 2026

MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with positive GAAP operating income and initiated the full year 2026 guidance. Full Year 2026 Guidance Full year 2026 total revenue of $415 million to $430 million, representing growth of 40% to 45% compared to the mi ...